Abu Dhabi Wants to Own Longevity Biotech—and Juvenescence Is the Test Case
Abu Dhabi’s push to become a global life-sciences hub has
A pill to live to 150? China’s grapeseed longevity hype gets right — and wrong
Lonvi Biosciences says its procyanidin C1 capsule could, one day,
A one-time gene edit for cholesterol: promise, price and the risks we can’t yet see
Early data from a tiny trial suggest that a single
The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger
As the GLP-1 gold rush enters its most aggressive phase,
Intellia’s gene-editing drug faces a liver-safety test as Phase 3 trials pause
Standfirst: A hospitalised patient with a Hy’s-law-like profile has forced
Base & Prime Editing Move from Hype to Timelines: What Hits Patients 2026–2030?
Beyond CRISPR Hype Gene editing has promised to revolutionize medicine,
From Hope to Proof: How Prasad’s FDA Could Reshape Biotech Approvals
When Dr. Vinay Prasad was abruptly removed from his FDA
Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide
In a strategic move poised to reshape the landscape of
AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal
AbbVie, a leading biopharmaceutical company, has taken a significant step
Metsera’s Weight-Loss Drug MET-097i Shows Strong Clinical Results
Obesity remains a critical public health challenge in the United
Breaking Barriers: BioArctic’s Blood-Brain Transport Technology and Its Impact on Neurological Drug Delivery
BioArctic, a Swedish biotechnology company renowned for its innovative approach
German Biotech CatalYm Raises $150 Million for Phase 2b Cancer Studies
CatalYm, a German biotech company specializing in cancer immunotherapy, has
Myricx Bio’s NMTi-ADCs Achieve Tumor Regression in Preclinical Trials
The field of cancer treatment is on the cusp of
UroGen Aims to Raise $107M to Advance Innovative Obesity and Bladder Cancer Therapies
Introduction Overview of UroGen: UroGen Pharma Ltd., headquartered in Princeton,
Marea Biotech Secures $190 Million for Heart Disease Research
Introduction Marea Biotech, a pioneering company in the biotech industry,
AI-Powered Drug Repurposing by BioXcel Therapeutics Accelerates Development of New Neuropsychiatric Treatments
1. Introduction BioXcel Therapeutics is a biopharmaceutical company leveraging artificial
Forbion-Backed VectorY Therapeutics Raises $138M for ALS and Neurodegenerative Disease Research
VectorY Therapeutics, a biotechnology company based in Amsterdam, Netherlands, has
MOST POPULAR
